Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours

Full text
Author(s):
Paiva, C. E. [1] ; Drigo, S. A. [2] ; Rosa, F. E. [2] ; Neto, F. A. Moraes [3] ; Caldeira, J. R. F. [4] ; Soares, F. A. ; Domingues, M. A. C. [5] ; Rogatto, S. R. [2]
Total Authors: 8
Affiliation:
[1] Sao Paulo State Univ, Oncol & Hematooncol Ctr, Botucatu, SP - Brazil
[2] Sao Paulo State Univ, Dept Urol, NeoGene Lab, Botucatu, SP - Brazil
[3] Amaral Carvalho Hosp, Dept Pathol, Jau, SP - Brazil
[4] Amaral Carvalho Hosp, Dept Senol, Jau, SP - Brazil
[5] Sao Paulo State Univ, Dept Pathol, Sao Paulo - Brazil
Total Affiliations: 5
Document type: Journal article
Source: Annals of Oncology; v. 21, n. 4, p. 734-740, APR 2010.
Web of Science Citations: 15
Abstract

Background: The clinical relevance of transforming growth factor-beta (TGF-beta)-signalling pathway in breast carcinomas (BCs) remained elusive. This study aimed to evaluate the prognostic value of TGF-beta and transforming growth factor-beta type II receptor (TGF-beta RII) expression levels in tumour cells and their association with the established biomarkers in BC. Patients and methods: In 324 BC from patients with long-term follow-up, the TGF-beta 1 and TGF-beta RII transcript and protein expression levels were assessed. Results: TGF-beta 1 and TGF-beta RII down-expression was significantly associated with BC. Negative TGF-beta 1 and TGF-beta RII protein status was associated with the development of distant metastasis (P = 0.003 and P = 0.029, respectively). In multivariate analysis, TGF-beta 1-positive tumours were associated with increased disease-free survival (DFS) {[}hazard ratio (HR) = 0.489, P = 0.003]. TGF-beta RII positivity was an independent prognostic factor for DFS (HR = 0.439, P = 0.001) and overall survival (OS) (HR = 0.409, P = 0.003) in human epidermal growth factor receptor2 (HER2)-negative patients. Absence of TGF-beta 1 and TGF-beta RII proteins in breast tumour cells was significantly associated with metastasis development. Conclusions: To the best of our knowledge, this is the first report indicating the relevance of HER2 status in discriminating TGF-beta RII as a prognostic marker for DFS and OS in human BC. These data indicate that TGF-beta RII protein analysis in tumour cells could be introduced in clinical practice as additional prognostic biomarker in HER2-negative BC. (AU)